JPRN-UMIN000028055招募中未知
Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastim - Discontinuation of PegG
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe myelosuppression 2)Active infection (except viral hepatitis) 3)Serious complications (organ failure, or active peptic ulcer etc) 4)Severe diarrhea 5)Intestinal pneumonitis or pulmonary fibrosis 6)Treatment-resistant ascites or pleural effusion 7)Brain or meningeal metastasis 8)Pregnancy or breast-feeding 9)Any contraindication for FOLFIRINOX 10)Severe complication by administration of pegfilgrastim 11)Severe mental disorder, or central nervous system disorders 12)Contraindication for dynamic CT/MRI 13)Inappropriate for this study judged by the investigator
研究者
相似试验
招募中
2 期
eoadjuvant FOLFIRINOXPancreatic cancer, Neoadjuvant therapyPancreatic cancerJPRN-jRCT1041220027Yamashita Tatsuya50
未知
2 期
A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancerpreviously untreated pancreatic cancerJPRN-jRCT2080221426Yakult Honsha Co.,Ltd.35
已完成
2 期
Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic canceruntreated metastatic pancreatic cancerJPRN-UMIN000013301Cancer Institute Hospital65
已完成
不适用
Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancerunresectable and recurrence pancreatic cancerJPRN-UMIN000014658Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)329
已完成
2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000015376Gifu University Hospital28